Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Issued (2016 - 2025)

Historic Shares Issued for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $39.5 million.

  • Altimmune's Shares Issued rose 2832949.64% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 1412149.53%. This contributed to the annual value of $10.0 million for FY2024, which is 8845.97% down from last year.
  • Altimmune's Shares Issued amounted to $39.5 million in Q3 2025, which was up 2832949.64% from $37.8 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Shares Issued ranged from a high of $121.0 million in Q4 2022 and a low of $38000.0 during Q2 2024
  • Over the past 5 years, Altimmune's median Shares Issued value was $13.2 million (recorded in 2023), while the average stood at $22.2 million.
  • In the last 5 years, Altimmune's Shares Issued tumbled by 9971.25% in 2024 and then surged by 9943421.05% in 2025.
  • Over the past 5 years, Altimmune's Shares Issued (Quarter) stood at $12.5 million in 2021, then soared by 871.19% to $121.0 million in 2022, then tumbled by 99.58% to $510000.0 in 2023, then surged by 1791.76% to $9.6 million in 2024, then skyrocketed by 309.59% to $39.5 million in 2025.
  • Its last three reported values are $39.5 million in Q3 2025, $37.8 million for Q2 2025, and $34.7 million during Q1 2025.